COMPANY:

NuProbe

"Bio-Rad Laboratories...and NuProbe USA...today announced the signing of a licensing and product development agreement. Under the terms of the agreement, NuProbe USA will exclusively license its allele enrichment technologies to Bio-Rad for the development of multiplexed digital PCR assays. This technology will help to advance Bio-Rad’s menu of products in oncology, where highly sensitive and multiplexed mutation detection assays aid translational research, therapy selection and disease monitoring."

"Bio-Rad Laboratories and NuProbe USA announced on Friday that they have signed a licensing and development agreement for NuProbe's Blocker Displacement Amplification technology for allele enrichment...Under the terms of the agreement, NuProbe will exclusively license its allele enrichment technologies to Bio-Rad for the development of multiplexed digital PCR assays."

"Houston, April 19th / NuProbe...announces its recent publication in Nature Communications describing a massively multiplexed PCR primer design algorithm, named Simulated Annealing Design using Dimer Likelihood Estimation (SADDLE). The SADDLE algorithm is applicable to both real-time quantitation PCR (qPCR) assays and to next generation sequencing (NGS) panels. Unlike other highly multiplexed PCR approaches, NuProbe’s SADDLE approach uses computational primer design to minimize primer-dimer formation, and thus does not require enzymatic primers and primer-dimer removal. The publication demonstrated proof-of-concept experimental results in oncology, but the same approach could in principle be applied to a wide variety of clinical genomics applications including in infectious diseases and hereditary diseases."

"NuProbe scientists and collaborators recently announced research demonstrating the accurate quantitation of somatic mutations below 0.01% variant allele frequency (VAF). By integrating molecular barcoding technology with the Blocker Displacement Amplification (BDA) allele enrichment, the team invented the new quantitative BDA (QBDA) method that overcomes potential biases in BDA to enable accurate VAF quantitation. The findings, published in Nature Communications, are the latest research developed by NuProbe for molecular detection of minimal residual disease (MRD) for cancer applications."

"NuProbe...published research demonstrating new technology to qualitatively and quantitively detect multiple low-frequency variants in one quantitative PCR (qPCR) reaction. The new allele-specific BDA technology (As-BDA) uses qPCR to detect mutations down to 0.01% variant allele fraction (VAF) within 2 hrs...As-BDA identifies variants with high sensitivity and specificity, making it advantageous and potential in non-invasive mutation profiling with liquid biopsy for cancer diagnosis and monitoring, where mutation VAF is usually very low."

"NuProbe...announced new published data in Nature Communications describing the use of Quantitative Amplicon Sequencing (QASeq) to simultaneously detect copy number variations (CNVs) and mutations from the same sample. The results show detection of CNVs down to 5% heterozygous single copy gain or loss, and mutations down to 0.1% variant allele frequency (VAF), from both formalin-fixed, paraffin-embedded (FFPE) tissue samples and from cell-free DNA (cfDNA) samples."

"C2i Genomics...today announced its technology co-development and expansion into China via a strategic partnership with NuProbe Global, a genomics and molecular diagnostics company specializing in ultrasensitive sequencing panels. The strategic alliance will power high-impact pharmaceutical and diagnostic services, leveraging C2i Genomics’ artificial intelligence (AI)-powered cancer intelligence platform across NuProbe’s chemistry products and sequencing networks in both China and the United States...As part of this collaboration, NuProbe and C2i will engage in the co-development of chemistry and software products that will expand the traditional whole-genome library preparation to include additional signal enrichment for cancer hotspots, Microsatellite instability (MSI) and fusions."

"NuProbe Global...have entered into a procurement and collaboration agreement, where NuProbe will integrate their Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA) technologies with Bionano’s Saphyr system for research and product development in the fields of...oncology liquid biopsies."

"NuProbe Global...announced research on DNA microsatellites published today in Nucleic Acids Research. Simultaneously, the company announced the release of the VarTrace® MSI qPCR research use only assay for detection of DNA microsatellite instability (MSI) from tissue or blood samples...The VarTrace MSI qPCR assay features a lower limit of detection of 1% variant allele frequency, when compared to gold standard capillary electrophoresis MSI assays in use today."

"NuProbe Global...announced research demonstrating the ability to detect single nucleotide variants (SNVs) in DNA with a variant allele frequency (VAF) of ≤0.02% using a sequencing depth of only 250x. The findings, published today in Nature Biomedical Engineering, are the latest research involving the blocker displacement amplification (BDA) technology, a novel PCR-based enrichment method that enables the selective amplification of low abundant sequence variants (SNVs and indels) in a background of wildtype DNA."

"Molecular diagnostics firm NuProbe said Tuesday that it has reached a strategic collaboration agreement with Beijing-based AcornMed Biotechnology to develop products for minimal residual disease detection in genitourinary tract cancer and hematological cancer using NuProbe's blocker displacement amplification, or BDA, technology...NuProbe and AcornMed aim to validate the chemistry for repeat testing of urine or plasma samples to monitor cancer treatment efficacy and guide clinician decision-making."

"NuProbe...launches its VarMapTM Pan-Cancer NGS Panel. The VarMapTM Pan-Cancer NGS Panel uses the quantitative blocker displacement amplification (QBDA) technology to enrich, detect, and quantitate over 6500 mutations and indels in 61 clinically relevant genes. The panel can be used on cfDNA samples to detect mutations down to 0.1% variant allele frequency (VAF) using only 1 million NGS reads. The panel can also be applied to FFPE tumor samples or other cellular samples for minimum residual disease (MRD) detection, detecting mutations down to 0.01% VAF."

"NuProbe...announces the launch of the Augury™ platform for automated design of customized liquid biopsy NGS panels. Based on proprietary sequence-design algorithms, Augury™ will procedurally generate NGS panels for cell-free DNA (cfDNA) analysis, covering the entire coding regions of between 1 and 30 genes of interest."